Zacks Research Estimates Omnicell FY2027 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Omnicell in a research report issued on Tuesday, February 25th. Zacks Research analyst R. Department anticipates that the company will post earnings per share of $1.36 for the year. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share.

Other analysts have also recently issued research reports about the company. Craig Hallum raised their target price on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. JPMorgan Chase & Co. upped their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Wells Fargo & Company decreased their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Benchmark reiterated a “buy” rating and set a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $52.33.

Omnicell Stock Performance

Shares of OMCL opened at $38.47 on Wednesday. The company has a 50-day moving average of $42.53 and a two-hundred day moving average of $43.82. Omnicell has a one year low of $25.12 and a one year high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of 142.49, a PEG ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%.

Hedge Funds Weigh In On Omnicell

Institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. raised its position in shares of Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after acquiring an additional 1,138,921 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of Omnicell in the 3rd quarter valued at approximately $32,721,000. Lazard Asset Management LLC boosted its position in shares of Omnicell by 81.6% during the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after purchasing an additional 737,536 shares in the last quarter. Toronto Dominion Bank acquired a new position in Omnicell in the fourth quarter valued at about $30,637,000. Finally, Dimensional Fund Advisors LP increased its stake in Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after purchasing an additional 394,820 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Insider Transactions at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.64% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.